BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32680476)

  • 1. The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma.
    Gan C; Pierscianek D; El Hindy N; Ahmadipour Y; Keyvani K; Sure U; Zhu Y
    BMC Cancer; 2020 Jul; 20(1):672. PubMed ID: 32680476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
    Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
    J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
    Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
    J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
    Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
    J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of ALDH1A3 promoter methylation in gliob;astoma: a single center experience in Western China.
    Ni W; Luo L; Ping Z; Yuan HP; Zhao XD; Xu W
    Asian Pac J Cancer Prev; 2015; 16(2):591-4. PubMed ID: 25684492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
    von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F
    J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
    Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
    Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
    Schiffgens S; Wilkens L; Brandes AA; Meier T; Franceschi E; Ermani M; Hartmann C; Sandalcioglu IE; Dumitru CA
    Oncotarget; 2016 Aug; 7(34):55169-55180. PubMed ID: 27409829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis.
    Zhao H; Wang S; Song C; Zha Y; Li L
    World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
    Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
    Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients.
    Wang X; Zhang K; Chen X; Zhao C; Sun Z
    Med Oncol; 2015 Jan; 32(1):363. PubMed ID: 25429835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
    Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
    J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme.
    El Hindy N; Keyvani K; Pagenstecher A; Dammann P; Sandalcioglu IE; Sure U; Zhu Y
    Neuro Oncol; 2013 Oct; 15(10):1366-78. PubMed ID: 23787764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.